Bradley Rosenberg, MD
Urology · Royal Oak, MINPI 1295718559
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (41.0%), education and travel and lodging — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 61.6% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2022 at $2,330 and has fallen 73.7% since, to $613 in 2025.
Across 72 payments — averaging $63.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$3K
- Agiliti Surgical, Inc.$284
- Ferring Pharmaceuticals Inc.$139
- Boston Scientific$123
- Calyxo, Inc.$123
- Johnson & Johnson$114
- plus $970 from 21 others
What the payments were for
- Travel & lodging$1,19426%
- Food & beverage$1,87541%
- Education$1,50033%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 10 | $2,816 |
| Agiliti Surgical, Inc. | 3 | $284 |
| Ferring Pharmaceuticals Inc. | 7 | $139 |
| Boston Scientific | 5 | $123 |
| Calyxo, Inc. | 2 | $123 |
| Johnson & Johnson(2 entities) | 6 | $114 |
| Dornier Medtech America, Inc | 1 | $105 |
| Olympus America Inc. | 4 | $100 |
| Amgen | 1 | $93 |
| Urogen Pharma, Inc. | 4 | $93 |
| Astellas Pharma US Inc | 4 | $76 |
| Novartis | 3 | $71 |
| Laborie Medical Technologies Corp. | 3 | $47 |
| Sumitomo Pharma America, Inc. | 3 | $47 |
| GSK | 2 | $46 |
| AbbVie | 2 | $41 |
| Cycle Pharmaceuticals Inc | 2 | $34 |
| Avyxa Pharma, LLC | 1 | $30 |
| Analogic Corporation | 1 | $27 |
| Pfizer | 1 | $26 |
| Dendreon Pharmaceuticals LLC | 1 | $25 |
| Antares Pharma, Inc. | 1 | $22 |
| Immunitybio, Inc. | 1 | $20 |
| Curium US LLC | 1 | $19 |
| Accord Healthcare, Inc. | 1 | $18 |
| Tolmar, Inc. | 1 | $16 |
| Photocure Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DA VINCI SP$1,500
- Da Vinci Surgical System$1,285
- Sonablate$152
- Sonablate HIFU$106
- Siemens Healthineers Varian CryoCare$106
- Dornier MedTech$105
How this compares
$4,568 in reported general payments places this provider in the 60th percentile of 400 urology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 73 | $67,963 |
| OrgovyxRelugolix | 13 | $31,158 |
| GemtesaVibegron | 25 | $17,178 |
| Potassium Citrate ErPotassium Citrate | 79 | $12,307 |
| Mirabegron ErMirabegron | 20 | $11,728 |
| Terazosin Hcl | 434 | $10,100 |
| Tamsulosin Hcl | 495 | $9,363 |
| Finasteride | 369 | $6,650 |
| Methenamine Hippurate | 42 | $4,196 |
| Bicalutamide | 42 | $2,759 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 83 | $2,508 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 11 | $1,969 |
| Silodosin | 19 | $1,948 |
| NitrofurantoinNitrofurantoin Macrocrystal | 47 | $1,469 |
| Dutasteride | 34 | $1,456 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $76 | $67,96373 claims |
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $47 | $48,33638 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 400 urology providers in Michigan.
Other urology in Royal Oak
- Richard BennettRoyal Oak$361K
- Kenneth PetersRoyal Oak$28K
- Adam GadzinskiRoyal Oak$22K
- Ashok ReddySterling Heights$4.9M
- William RobertsAnn Arbor$973K
- Kenneth KernenTroy$910K
- William JohnstonLivonia$675K
- Jason HafronWest Bloomfield$490K
- Khurshid GhaniAnn Arbor$413K
- Ryan NelsonUtica$296K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.